176 related articles for article (PubMed ID: 35481791)
1. Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Cheok KPL; Kirkwood AA; Menne T; Tholouli E; Chaganti S; Mathew A; Uttenthal B; Russell J; Irvine D; Johnson R; Nicholson E; Bazin J; Townsend W; Kuhnl A; O'Reilly M; Sanderson R; Patel A; Roddie C
Leuk Lymphoma; 2022 Aug; 63(8):1980-1984. PubMed ID: 35481791
[No Abstract] [Full Text] [Related]
2. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
3. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
Wu X; Wang L; Shen L; He L; Tang K
J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
[TBL] [Abstract][Full Text] [Related]
4. Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.
Hong R; Zhao H; Wang Y; Chen Y; Cai H; Hu Y; Wei G; Huang H
Bone Marrow Transplant; 2021 Mar; 56(3):570-580. PubMed ID: 32943758
[TBL] [Abstract][Full Text] [Related]
5. Prolonged SARS-CoV-2 Infection in a CAR T-Cell Therapy Recipient.
Abbasi J
JAMA; 2021 Mar; 325(10):924. PubMed ID: 33687450
[No Abstract] [Full Text] [Related]
6. An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experience.
Scourfield L; Pirani T; Singh N; Saha R; Kuhnl A; Sanderson R; Metaxa V
J Crit Care; 2024 Apr; 80():154511. PubMed ID: 38157684
[No Abstract] [Full Text] [Related]
7. SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments.
Parvathaneni K; Torres-Rodriguez K; Meng W; Hwang WT; Frey N; Naji A; Bhoj VG
JAMA Oncol; 2022 Jan; 8(1):164-167. PubMed ID: 34792539
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 in patients with cancer: Risks and precautions.
Razavi A; Hamblin MR; Rezaei N
Am J Emerg Med; 2021 Oct; 48():357-360. PubMed ID: 33546958
[TBL] [Abstract][Full Text] [Related]
9. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines
Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
Front Immunol; 2021; 12():652223. PubMed ID: 34367128
[TBL] [Abstract][Full Text] [Related]
10. Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects.
Chen Y; Liu C; Fang Y; Chen W; Qiu J; Zhu M; Wei W; Tu J
Biochem Pharmacol; 2024 Apr; 222():116066. PubMed ID: 38373592
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
Front Immunol; 2021; 12():763460. PubMed ID: 35003077
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
13. Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK.
Pirani T; Wilson A; Brealey D; Low R; O'Neill S; Le J; Jhanji S; Bangash MN; Mathew A; Wright C; Latif AL; Irvine D; Kasipandian V; Singh N; Saha R; Metaxa V
Br J Anaesth; 2024 May; 132(5):1004-1006. PubMed ID: 38521658
[No Abstract] [Full Text] [Related]
14. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Rogosic S; Ghorashian S
Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
[TBL] [Abstract][Full Text] [Related]
15. CAR T-cell therapy: perceived need versus actual evidence.
The Lancet Oncology
Lancet Oncol; 2018 Oct; 19(10):1259. PubMed ID: 30303110
[No Abstract] [Full Text] [Related]
16. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
17. Safer CAR T-Cell Therapy.
Abbasi J
JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
[No Abstract] [Full Text] [Related]
18. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
19. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
20. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
